Drugs / ATIR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01794299 | Mar 2013 → Jun 2016 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Kiadis Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATIR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01794299 ↗ |
| Modality | Cell therapy | “Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells” NCT01794299 ↗ |
| Route | Intravenous | “Single intravenous infusion” NCT01794299 ↗ |